Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Institut Claudius Regaud Hoffmann-La Roche |
---|---|
Information provided by: | Institut Claudius Regaud |
ClinicalTrials.gov Identifier: | NCT00144976 |
The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.
Condition | Intervention |
---|---|
Head and Neck Neoplasms |
Drug: Tarceva |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up. |
Enrollment: | 43 |
Study Start Date: | October 2003 |
Study Completion Date: | December 2006 |
Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
Patients will receive Tarceva in continuous between 18 and 28 days after pan-endoscopy exam until surgery
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
Institut claudius regaud | |
Toulouse, France | |
Center Oscar Lambret | |
Lille, France |
Principal Investigator: | Jean Pierre Delord, Docteur | Institut Claudius Regaud |
Responsible Party: | Institut Claudius Regaud ( Dr Jean-Pierre DELORD ) |
Study ID Numbers: | 03 VADS 01 |
Study First Received: | September 2, 2005 |
Last Updated: | May 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00144976 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
Head and Neck Neoplasms Tarceva ENT |
Erlotinib Epidermoid carcinoma Squamous cell carcinoma Head and Neck Neoplasms Carcinoma, squamous cell |
Neoplasms, Squamous Cell Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action |
Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |